6 results
Thumbnail

D3.390 - Rationale and Design for ALPHA-ORBIT: a phase 3 trial of navenibart, a monoclonal antibody inhibitor of plasma kallikrein for participants with hereditary angioedema (HAE)

Thumbnail

D3.391 - Results from the ALPHA-STAR Trial, a Phase 1b/2 Single and Multiple Dose Study to Assess the Safety, Tolerability, Clinical Activity, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Navenibart in Participants with Hereditary Angioedema (HAE)

Thumbnail

D3.436 - Advancing Equity in Food Allergy Prevention – Insights and Takeaways from CFAAR’s Summit for Advancing Equity in Food Allergy

Thumbnail

D3.437 - An EAACI Task Force Initiative for Visualizing Historical Pollen and Spore Calendars in Europe

Thumbnail

D3.438 - Advances in Automated Pollen Monitoring in Mediterranean Regions: New Developments from the SYLVA Project in Córdoba (Spain)

Thumbnail

D3.439 - On-demand treatment of hereditary angioedema attacks: Assessing self-treatment, outcomes and barriers to early intervention